[Skip to Navigation]
December 1974

New Concepts in Management of Otospongiosis

Author Affiliations

From the Otologic Professional Associates and the Department of Otolaryngology and Maxillofacial Surgery of Northwestern University Medical School, sponsored by the Mid America Hearing Research Foundation, Chicago (Dr. Shambaugh); the Causse Clinic, Beziers, France (Dr. Causse); the University of Strasbourg, Strasbourg, France (Dr. Petrovic); the Pasteur Institute, Paris (Dr. Chevance); and the University of Illinois, Chicago (Dr. Valvasorri).

Arch Otolaryngol. 1974;100(6):419-426. doi:10.1001/archotol.1974.00780040433003

Polytef (Teflon) piston against vein graft stapedectomy is currently preferred with frequent assessment of cochlear function during the first three critical weeks so that medical therapy can be directed toward any cochlear drop.

Moderate dosage of sodium fluoride is recommended preoperatively for six months to one year, for active otospongiosis. Postoperatively it is prescribed for two years or longer for active cochlear otospongiosis with skeletal surveys once every two years to monitor the skeletal effects.

Preliminary data indicate a favorable effect of moderate dosage sodium fluoride in a high percentage of patients in arresting progressive sensorineural loss due to otospongiosis. This treatment is as safe and perhaps safer than a moderate dosage of aspirin.